Cytokines in multiple sclerosis: Methodological aspects and pathogenic implications

Multiple Sclerosis

Volumn 8, Issue 5, 2002, Pages 396-404

  Özenci, Volcan ^a   Kouwenhoven, M ^a   Link, H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokines; ELISPOT assays; Immunology; Methods; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CELL ADHESION MOLECULE; CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LENERCEPT; MATRIX METALLOPROTEINASE; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PLACEBO; PROTEIN P40; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CAUCASIAN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEMYELINATION; DISABILITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMAGING SYSTEM; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGY; LEUKOCYTE MIGRATION; METHODOLOGY; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; NORTHERN BLOTTING; OLIGODENDROGLIA; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTIBODY FORMATION; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; LEUKOCYTES; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; RESEARCH;

EID: 0036783423     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms837rr     Document Type: Review

References (82)

1. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation
2. Exacerbations of multiple sclerosis in patients treated with gamma interferon
3. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, placebo-controlled trial
4. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
5. Anti-inflammatory cytokines
6. Anti-inflammatory cytokine profile and mortality in febrile patients
7. Cytokines and the pathogenesis of multiple sclerosis
8. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
9. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity
10. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls
11. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis
12. Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis
13. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ
14. Model systems for studies of leukocyte migration across the blood-brain barrier
15. The role of CD40 ligand costimulation and T-cell activation
16. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease
17. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions
18. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment
19. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
20. Interleukin-12
21. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
22. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
23. Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo
24. Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis
25. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
26. Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation
27. Interleukin-12 is detectable in sera of patients with multiple sclerosis - Association with chronic progressive disease course?
28. IL-12/IL-12R system in multiple sclerosis
29. IL-12 ELISPOT assays to detect and enumerate IL-12 secreting cells
30. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients
31. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis
32. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage
33. Flow cytometric analysis of in vitro proinflammatory cytokine secretion in peripheral blood from multiple sclerosis patients
34. Cytokine analysis in multiple sclerosis by competitive RT-PCR: A decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression
35. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS
36. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment
37. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment
38. Differential effects of cytokines and immunosuppressive drugs on CD40, B7-1, and B7-2 expression on purified epidermal Langerhans cells1
39. Rheumatoid arthritis
40. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
41. Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis
42. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
43. Interleukin 6 and its receptor: Ten years later
44. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators
45. Interleukin-6 is elevated in plasma in multiple sclerosis
46. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis
47. Interleukin-10
48. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium
49. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse
50. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
51. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis
52. Low serum interleukin-10 levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression?
53. The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion
54. Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokine expression
55. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
56. Immune regulation within the central nervous system
57. Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies?
58. Cytokines and cerebrospinal fluid: Methodology, findings and clinical relevance in multiple sclerosis
59. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
60. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis
61. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6
62. Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: Detection by RT-PCR without in vitro stimulation
63. The adhesion molecule and cytokine profile of multiple sclerosis lesions
64. IL-6 detection in multiple sclerosis brain
65. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology
66. Genetic models for CNS inflammation
67. Mechanisms of immune injury in multiple sclerosis
68. Interferon-gamma-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis
69. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death
70. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview
71. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS
72. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis
73. B cells and autoimmunity
74. Identification of autoantibodies associated with myelin damage in multiple sclerosis
75. Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis
76. Oligodendrocyte injury and the role of complement in multiple sclerosis
77. The cytokine storm in multiple sclerosis
78. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis
79. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
80. Relapse markers in multiple sclerosis: Are in vitro cytokine production changes reflected by circulatory T-cell phenotype alterations?
81. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis
82. Monocytes in multiple sclerosis: Phenotype and cytokine profile